Display options
Cite
Madan RA, Gulley JL. Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. Immunotherapy. 2011;3(1):27-31doi: 10.2217/imt.10.77.
Madan, R. A., & Gulley, J. L. (2011). Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. Immunotherapy, 3(1), 27-31. https://doi.org/10.2217/imt.10.77
Madan, Ravi A, and Gulley, James L. "Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer." Immunotherapy vol. 3,1 (2011): 27-31. doi: https://doi.org/10.2217/imt.10.77
Madan RA, Gulley JL. Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. Immunotherapy. 2011 Jan;3(1):27-31. doi: 10.2217/imt.10.77. PMID: 21174555; PMCID: PMC3474245.
Copy Download .nbib Format: NLM
Share it on

Immunotherapy. 2011 Jan;3(1):27-31. doi: 10.2217/imt.10.77.

Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer.

Immunotherapy

Ravi A Madan, James L Gulley

Affiliations

  1. Laboratory of Tumor Immunology & Biology, Center for Cancer Research, National Cancer Institute, 10 Center Drive, 8B09 MSC 1750, Bethesda, MD 20892, USA.

PMID: 21174555 PMCID: PMC3474245 DOI: 10.2217/imt.10.77

Abstract

For many years, preclinical and clinical studies have attempted to harness the power of the immune system and focus it on malignant cells in an attempt to improve clinical outcomes for patients with cancer. This paper describes the landmark Phase III trial that led to the first US FDA approval of a therapeutic cancer vaccine. In a randomized trial of 512 patients, those treated with sipuleucel-T survived for 25.8 months compared with those treated with placebo, who survived 21.7 months (HR: 0.78; p = 0.03). There was, however, no change in time to progression, which may relate to the underlying mechanism of this new class of therapeutics.

References

  1. J Immunol. 2005 Sep 15;175(6):3715-23 - PubMed
  2. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  3. Ann Pharmacother. 2008 Jan;42(1):91-8 - PubMed
  4. J Clin Oncol. 2000 Dec 1;18(23):3894-903 - PubMed
  5. Anticancer Res. 2000 Sep- Oct;20(5B):3375-81 - PubMed
  6. J Urol. 1991 May;145(5):907-23 - PubMed
  7. Cancer Cell. 2005 Mar;7(3):239-49 - PubMed
  8. N Engl J Med. 2004 Oct 7;351(15):1502-12 - PubMed
  9. J Clin Oncol. 1994 Apr;12(4):689-94 - PubMed
  10. Curr Opin Mol Ther. 2002 Feb;4(1):76-9 - PubMed
  11. BJU Int. 2005 Nov;96(7):985-9 - PubMed
  12. J Clin Invest. 2008 Jun;118(6):1991-2001 - PubMed
  13. Front Biosci. 2007 Sep 01;12:4957-71 - PubMed
  14. Cancer. 2009 Aug 15;115(16):3670-9 - PubMed
  15. J Clin Oncol. 2006 Jul 1;24(19):3089-94 - PubMed
  16. Clin Cancer Res. 2000 Jun;6(6):2175-82 - PubMed
  17. Expert Rev Vaccines. 2006 Apr;5(2):199-209 - PubMed
  18. Clin Cancer Res. 2008 Jun 1;14(11):3536-44 - PubMed
  19. Cancer Immunol Immunother. 2000 Jul;49(4-5):181-5 - PubMed
  20. Endocr Relat Cancer. 2005 Dec;12(4):805-22 - PubMed
  21. J Clin Oncol. 2010 Mar 1;28(7):1099-105 - PubMed
  22. N Engl J Med. 2004 Oct 7;351(15):1513-20 - PubMed
  23. Curr Pharm Des. 2002;8(19):1765-80 - PubMed
  24. Cancer Immunol Immunother. 2010 May;59(5):663-74 - PubMed
  25. Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70 - PubMed
  26. J Clin Oncol. 2012 May 1;30(13):1534-40 - PubMed
  27. FEBS Lett. 1988 Aug 29;236(2):275-81 - PubMed
  28. J Immunol. 2003 Jun 15;170(12):6338-47 - PubMed

Publication Types

Grant support